Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) shares traded up 2.3% during trading on Thursday . The stock traded as high as $9.44 and last traded at $9.25, with a volume of 60,383 shares. The stock had previously closed at $9.04.

A number of research analysts recently issued reports on AQXP shares. Canaccord Genuity reiterated a “buy” rating and issued a $22.00 target price on shares of Aquinox Pharmaceuticals in a research note on Wednesday, August 17th. Zacks Investment Research lowered shares of Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, August 9th. Needham & Company LLC started coverage on shares of Aquinox Pharmaceuticals in a research note on Thursday, May 12th. They issued a “buy” rating and a $25.00 target price on the stock. Finally, Jefferies Group raised their target price on shares of Aquinox Pharmaceuticals from $7.00 to $9.00 and gave the company a “hold” rating in a research note on Friday, August 5th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $19.86.

The company’s market capitalization is $164.37 million. The firm’s 50 day moving average price is $8.53 and its 200 day moving average price is $8.38.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last announced its quarterly earnings results on Thursday, August 4th. The company reported ($0.63) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.41) by $0.22. On average, analysts predict that Aquinox Pharmaceuticals Inc. will post ($2.08) earnings per share for the current year.

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.